Abstract
Free full text
T cell–tumor cell: a fatal interaction?
Abstract
Fas (Apo-1/CD95) is a cell-surface protein that is responsible for initiating a cascade of proteases (caspases) culminating in apoptotic cell death in a variety of cell types. The function of the Fas/FasL system in the dampening of immune responses to infectious agents through the autocrine deletion of activated T cells has been well documented. More recently, it has been proposed that tumor cells express FasL, presumably to avoid immune detection. In this review, we focus on the role of the interaction of Fas and FasL in the modulation of antitumor responses. We critically examine the evidence that FasL is expressed by tumor cells and explore alternative explanations for the observed phenomena in vitro and in vivo. By reviewing data that we have generated in our laboratory as well as reports from the literature, we will argue that the Fas/FasL system isa generalized mechanism used in an autocrine fashion to regulate cell survival and expansion in response to environmental and cellular cues. We propose that FasL expression by tumor cells, when present, is indicative of a perturbed balance in the control of proliferation while “immune privilege” is established by “suicide” of activated antitumor T cells, a form of activation-induced cell death.
Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer
Full text links
Read article at publisher's site: https://doi.org/10.1007/s002620050505
Read article for free, from open access legal sources, via Unpaywall: https://europepmc.org/articles/pmc2249694?pdf=render
Citations & impact
Impact metrics
Citations of article over time
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1007/s002620050505
Article citations
The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma.
Sci Rep, 11(1):14838, 21 Jul 2021
Cited by: 14 articles | PMID: 34290294 | PMCID: PMC8295309
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
J Hematol Oncol, 13(1):110, 10 Aug 2020
Cited by: 599 articles | PMID: 32778143 | PMCID: PMC7418434
Review Free full text in Europe PMC
Fas Ligand (FasL) in Association with Tumor-Infiltrating Lymphocytes (TILs) in Early Stage Cervical Cancer.
Asian Pac J Cancer Prev, 21(3):831-835, 01 Mar 2020
Cited by: 4 articles | PMID: 32212814 | PMCID: PMC7437346
Fas-Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis.
Front Immunol, 7:382, 27 Sep 2016
Cited by: 79 articles | PMID: 27729910 | PMCID: PMC5037862
Review Free full text in Europe PMC
FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.
Tumour Biol, 36(6):4319-4326, 18 Jan 2015
Cited by: 2 articles | PMID: 25596086 | PMCID: PMC4529455
Go to all (30) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Leuk Lymphoma, 31(5-6):477-490, 01 Nov 1998
Cited by: 19 articles | PMID: 9922038
Review
Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
Dis Esophagus, 12(2):83-89, 01 Jan 1999
Cited by: 19 articles | PMID: 10466039
Review
Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction.
Int Rev Immunol, 18(5-6):485-513, 01 Jan 1999
Cited by: 31 articles | PMID: 10672498
Review
Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology.
Math Biosci, 179(2):113-129, 01 Sep 2002
Cited by: 21 articles | PMID: 12208611
Funding
Funders who supported this work.
Intramural NIH HHS (2)
Grant ID: Z99 CA999999
Grant ID: Z01 BC010763-01